DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phase 3

Completed

Conditions: Non-erosive Gastroesophageal Reflux Disease

Interventions: Drug: Placebo
Drug: TAK-438 10 mg

First Posted Date: 2016-11-04

Last Posted Date: 2019-08-02

Lead Sponsor: Takeda

Target Recruit Count: 484

Registration Number: NCT02954848

Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Phase 2

Completed

Conditions: Healthy Volunteers

Interventions: Biological: TDV

First Posted Date: 2016-10-28

Last Posted Date: 2024-03-15

Lead Sponsor: Takeda

Target Recruit Count: 200

Registration Number: NCT02948829

Locations: 🇵🇭
Research Institute for Tropical Medicine, Muntinlupa, Philippines
🇵🇦
CEVAXIN, Panama, Panama

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Phase 2

Completed

Conditions: Hodgkin Disease
Lymphoma, Large-Cell, Anaplastic

Interventions: Drug: Brentuximab Vedotin

First Posted Date: 2016-10-19

Last Posted Date: 2021-02-24

Lead Sponsor: Takeda

Target Recruit Count: 39

Registration Number: NCT02939014

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Sun Yat-san University Cancer Center, Guangzhou, Guangdong, China

and more 4 locations

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vortioxetine
Drug: Paroxetine
Drug: Placebo

First Posted Date: 2016-10-13

Last Posted Date: 2018-09-14

Lead Sponsor: Takeda

Target Recruit Count: 361

Registration Number: NCT02932904

Ixazomib Rollover Study

Phase 2

Completed

Conditions: Multiple Myeloma
Lymphoma
Amyloidosis

Interventions: Drug: Ixazomib

First Posted Date: 2016-10-05

Last Posted Date: 2025-03-12

Lead Sponsor: Takeda

Target Recruit Count: 32

Registration Number: NCT02924272

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇨🇦
University Health Network, Toronto, Ontario, Canada
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 23 locations

A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-28

Last Posted Date: 2021-01-12

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT02917941

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: Scopolamine
Drug: TAK-071
Drug: Donepezil
Drug: Scopolamine Placebo
Drug: TAK-071 Placebo
Drug: Donepezil Placebo

First Posted Date: 2016-09-28

Last Posted Date: 2019-06-14

Lead Sponsor: Takeda

Target Recruit Count: 18

Registration Number: NCT02918266

Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease

Phase 2

Withdrawn

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Vedolizumab intravenous injection
Drug: Vedolizumab subcutaneous injection

First Posted Date: 2016-09-23

Last Posted Date: 2016-09-23

Lead Sponsor: Takeda

Registration Number: NCT02913508

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-935 Tablets
Drug: TAK-935 Oral Solution

First Posted Date: 2016-09-20

Last Posted Date: 2018-09-19

Lead Sponsor: Takeda

Target Recruit Count: 9

Registration Number: NCT02906813

Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain

Completed

Conditions: Breakthrough Cancer Pain

Interventions: Other: No Intervention

First Posted Date: 2016-09-14

Last Posted Date: 2019-11-22

Lead Sponsor: Takeda

Target Recruit Count: 3765

Registration Number: NCT02899884

Locations: 🇪🇸
Hospital Universitario San Juan de Alicante, San Juan, Alicante, Spain
🇪🇸
Hospital General Universitario de Elda-Virgen de La Salud, Elda, Alicante, Spain
🇪🇸
Hospital Universitari Son Espases, Palma de Mallorca, Baleares, Spain

and more 33 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy